Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Prediction of immune therapy response with Ga-68 FAPI PET
研究概览
简要总结
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
详细描述
Patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study. Patients will undergo Ga68 FAPI PET/CT imaging within 10 days before the start of immunotherapy treatment, and SUVmax, SUVmean, metabolic tumor volume and total Ga68 FAPI uptake parameters will be obtained from the tumors. Following this, the routine treatment and follow-up of the patients will be carried out by their clinicians. It will be evaluated whether there is a correlation between treatment response and initial Ga-68 FAPI PET findings.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having a histopathologically confirmed diagnosis of
- •Pleural Mesolthelioma
- •Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
- •Patients who gave informed consent form to participate in the study
排除标准
- •Patients who did not provide informed consent form to participate in the study
结局指标
主要结局
Prediction of immune therapy response with Ga-68 FAPI PET
时间窗: 6. month after initiation of therapy
prediction of immunotherapy response with SUVmax measured with Ga-68 FAPI PET before immunotherapy
次要结局
未报告次要终点
研究者
Cigdem Soydal
AsC Prof of Nuclear Medicine
Ankara University